Senesco Technologies, Inc.
721 Route 202/206
Suite 130
Bridgewater
New Jersey
08807
United States
Tel: 908-864-4444
Fax: 908-864-4440
Website: http://www.senesco.com/
Email: info@senesco.com
167 articles about Senesco Technologies, Inc.
-
Senesco Technologies, Inc. Closes Enrollment In Its Phase 1b/2a SNS01-T Study
8/29/2014
-
Senesco Technologies, Inc. Presents Company Update At 2014 Biotechnology Industry Organization (BIO) International Convention
6/26/2014
-
Senesco Technologies, Inc. Brings In A New CEO
6/26/2014
-
Senesco Technologies, Inc. To Update On R&D Plans At Biotechnology Industry Organization (BIO)
6/19/2014
-
Senesco Technologies, Inc. Announces Update On SNS01-T At American Society of Clinical Oncology
6/2/2014
-
Senesco Technologies, Inc. Completes Acquisition Of Fabrus, An Opko Health, Inc. Portfolio Company
5/20/2014
-
Senesco Technologies, Inc. Completes Acquisition Of Fabrus LLC
5/19/2014
-
Senesco Technologies, Inc. Reports Second Quarter Of Fiscal Year 2014 Financial Results
5/12/2014
-
Senesco Technologies, Inc. Announces Presentation On The Effectiveness Of eIF5A In Inhibiting Tumor Progression In Liver Cancer Models
4/28/2014
-
Senesco Technologies, Inc. Opens Two New Clinical Trial Sites And Initiates Treatment Of The First Patient In South Africa
3/12/2014
-
In Non-clinical Cancer Studies Senesco Technologies, Inc.’s Therapeutic Candidate, SNS01-T, Works Synergistically In Combination With The Active Components Of Revlimid® And Velcade®
3/4/2014
-
Senesco Technologies, Inc. Reports Second Quarter Of Fiscal Year 2014 Financial Results
2/18/2014
-
Senesco Technologies, Inc. To Present At Biotech Showcase™ 2014
1/9/2014
-
First Patient In Cohort 4 Receives Infusion Of Senesco Technologies, Inc.’s Therapeutic Candidate, SNS01-T, For The Treatment Of Multiple Myeloma And Non-Hodgkins Lymphoma In Phase 1b/2a Clinical Trial
1/9/2014
-
Senesco Technologies, Inc., Fabrus LLC To Merge
12/30/2013
-
Senesco Technologies, Inc. Announces Up To $25.2 Million Equity Financing
12/12/2013
-
Senesco Technologies, Inc.'s Drug Candidate SNS01-T Selectively Kills Cancer Cells And Not Healthy Cells In Disease Models
12/10/2013
-
Senesco Technologies, Inc. Announces Results Of Cohort 3 In SNS01-T Phase 1b/2a Trial
12/9/2013
-
Senesco Technologies, Inc. Announces Results Of Cohort 3 In SNS01-T Phase 1b/2a Trial
12/9/2013
-
Senesco Technologies, Inc. Release: Completion Of Cohort 3 In Phase 1b/2a Study In Multiple Myeloma And Non-Hodgkins B-Cell Lymphoma
12/4/2013